Plasma trimethylamine-N-oxide, its precursors and risk of cardiovascular events in patients with acute coronary syndrome: Mediating effects of renal function.

acute coronary syndrome major adverse cardiovascular events metabolites prognostic trimethylamine-N-oxide

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2022
Historique:
received: 22 07 2022
accepted: 05 09 2022
entrez: 10 10 2022
pubmed: 11 10 2022
medline: 11 10 2022
Statut: epublish

Résumé

To examine associations of the gut microbial metabolite trimethylamine-N-oxide (TMAO) and its precursors with risk of cardiovascular events in acute coronary syndrome (ACS), and determine whether these associations were mediated by renal function. In this prospective cohort study, we included 309 patients with ACS. During a mean follow-up of 6.7 years, 131 patients developed major adverse cardiovascular events (MACE) (myocardial infarction, hospitalization for heart failure, and all-cause mortality). Plasma concentrations of TMAO, trimethylamine (TMA), choline, betaine, dimethylglycine and L-carnitine were profiled by liquid chromatography tandem mass spectrometry. Hazard ratios were estimated with multivariable Cox regression models. The mediating role of estimated glomerular filtration rate (eGFR) was tested under a counterfactual framework. After adjustment for traditional cardiovascular risk factors and medications, participants in the highest tertile vs. the lowest tertile of baseline TMAO and dimethylglycine concentrations had a higher risk of MACE [(HR: 1.83; 95% CI: 1.08, 3.09) and (HR: 2.26; 95% CI: 1.17, 3.99), respectively]. However, with regards to TMAO these associations were no longer significant, whereas for dimethylglycine, the associations were attenuated after additional adjustment for eGFR. eGFR mediated the associations of TMAO (58%) and dimethylglycine (32%) with MACE incidence. The associations between dimethylglycine and incident MACE were confirmed in an internal validation. No significant associations were found for TMA, choline, betaine and L-carnitine. These findings suggest that renal function may be a key mediator in the association of plasma TMAO with the development of cardiovascular events after ACS. The present findings also support a role of dimethylglycine in the pathogenesis of MACE, which may be mediated, at least partially, by renal function.

Identifiants

pubmed: 36211587
doi: 10.3389/fcvm.2022.1000815
pmc: PMC9532606
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1000815

Informations de copyright

Copyright © 2022 Sanchez-Gimenez, Peiró, Bonet, Carrasquer, Fragkiadakis, Bulló, Papandreou and Bardaji.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Med. 2022 Feb;28(2):303-314
pubmed: 35177860
Antioxidants (Basel). 2019 May 01;8(5):
pubmed: 31052417
BMC Cardiovasc Disord. 2020 Aug 28;20(1):394
pubmed: 32859154
Circulation. 2013 Jan 29;127(4):e362-425
pubmed: 23247304
Toxins (Basel). 2019 Nov 01;11(11):
pubmed: 31683880
Circ Res. 2015 Jan 30;116(3):448-55
pubmed: 25599331
Circulation. 2014 Dec 23;130(25):e344-426
pubmed: 25249585
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
PLoS One. 2019 Aug 28;14(8):e0221044
pubmed: 31461449
Atherosclerosis. 2015 Dec;243(2):638-44
pubmed: 26554714
Environ Sci Technol. 2014 Feb 18;48(4):2097-8
pubmed: 24476540
J Am Heart Assoc. 2018 Sep 18;7(18):e009885
pubmed: 30371188
Eur Heart J. 2014 Apr;35(14):904-10
pubmed: 24497336
Eur Heart J. 2017 Mar 14;38(11):814-824
pubmed: 28077467
Nutr Res. 2011 Jul;31(7):563-71
pubmed: 21840473
Sci Rep. 2017 Oct 23;7(1):13781
pubmed: 29061990
Nutrients. 2022 Jun 27;14(13):
pubmed: 35807835
Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):2041-8
pubmed: 23723367
BMC Cardiovasc Disord. 2020 Jan 9;20(1):7
pubmed: 31918665
PLoS One. 2012;7(5):e37883
pubmed: 22649561
PLoS One. 2016 Jan 11;11(1):e0141738
pubmed: 26751065
Eur Heart J. 2014 Mar;35(9):552-6
pubmed: 24357507
Kidney Int. 2001 Jun;59(6):2267-72
pubmed: 11380830
World J Nephrol. 2012 Oct 6;1(5):134-45
pubmed: 24175251
Clin Biochem Rev. 2016 Feb;37(1):17-26
pubmed: 27057075
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Sci Rep. 2016 Nov 08;6:36359
pubmed: 27821850
Eur J Prev Cardiol. 2015 Jun;22(6):743-52
pubmed: 24671904
Epidemiol Health. 2017 Aug 6;39:e2017035
pubmed: 29121709
Int Urol Nephrol. 2021 Mar;53(3):539-551
pubmed: 32945995
Ann Transl Med. 2016 Jul;4(13):258
pubmed: 27500159
Clin Chem. 2021 Jan 8;67(1):288-297
pubmed: 33257943
Arch Biochem Biophys. 1998 Aug 1;356(1):93-8
pubmed: 9681996
J Immunol Res. 2020 Aug 18;2020:4904217
pubmed: 32908939
Stat Med. 2005 Dec 30;24(24):3871-85
pubmed: 16320260
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
BMC Med Res Methodol. 2012 Mar 23;12:34
pubmed: 22443286
Biol Chem. 2017 Jun 27;398(7):775-784
pubmed: 27902449

Auteurs

Raul Sanchez-Gimenez (R)

Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.

Óscar M Peiró (ÓM)

Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.

Gil Bonet (G)

Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.

Anna Carrasquer (A)

Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.

Georgios A Fragkiadakis (GA)

Department of Nutrition and Dietetics Sciences, School of Health Sciences, Hellenic Mediterranean University (HMU), Siteia, Greece.

Mònica Bulló (M)

Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Department of Biochemistry and Biotechnology, Rovira i Virgili University, Reus, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.

Christopher Papandreou (C)

Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.

Alfredo Bardaji (A)

Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.

Classifications MeSH